ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.60
0.00%
US Tech 100
19,437.20
0.18%
S&P 500
5,473.23
0.77%
US Dollar vs CAD
1.37485
0.25%
Bitcoin
65,480.46
-1.51%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. PHAXIAM Therapeutics SA (PHXM)

  7. PHAXIAM Therapeutics SA (PHXM) News

PHXM

PHAXIAM Therapeutics (PHXM)

PHAXIAM Therapeutics SA
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PHXM
DateTimeSourceHeadlineSymbolCompany
03/11/20247:31AMEdgar (US Regulatory)Form 15F-12B - Securities registration termination of foreign private issuers [Section 12(b)]NASDAQ:PHXMPHAXIAM Therapeutics SA
03/11/20241:00AMGlobeNewswire Inc.PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketNASDAQ:PHXMPHAXIAM Therapeutics SA
03/05/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PHXMPHAXIAM Therapeutics SA
03/04/20243:28PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
03/04/20243:27PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
03/04/20243:25PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
03/04/20243:22PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
03/04/20243:14PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
03/04/20243:09PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PHXMPHAXIAM Therapeutics SA
02/21/20245:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
02/20/20243:05PMGlobeNewswire Inc.PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketNASDAQ:PHXMPHAXIAM Therapeutics SA
01/19/20249:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
01/18/20243:05PMGlobeNewswire Inc.PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024NASDAQ:PHXMPHAXIAM Therapeutics SA
11/16/20236:41AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
11/14/20233:05PMGlobeNewswire Inc.PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023NASDAQ:PHXMPHAXIAM Therapeutics SA
10/25/20238:21AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
10/24/20233:05PMGlobeNewswire Inc.PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureusNASDAQ:PHXMPHAXIAM Therapeutics SA
10/23/20233:05PMGlobeNewswire Inc.TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendationNASDAQ:PHXMPHAXIAM Therapeutics SA
10/11/20235:53AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
10/05/20236:32AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
09/26/20232:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
09/21/20237:42AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
09/18/20237:16AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
09/15/20237:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
09/07/20238:33AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
07/27/20233:21PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
 Showing the most relevant articles for your search:NASDAQ:PHXM

Your Recent History

BITV
ENJBTC
Enjin Coin
EU
BE0002655364
SD Worx Holding 3.8% 11j...
COIN
PATBTC
PATRON
TIDE
DOGEBTC
Dogecoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved